CLDX, US15117B2025

Celldex Therapeutics stock reports strong Phase 3 trial results

Published on 10/05/2026 at 15:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Celldex Therapeutics stock was last at USD 31.65 on October 2 after a 1.65 percent decline. Phase 3 data covered 1,939 patients and sustained response rates.

CLDX, US15117B2025, Illustration mit AI erstellt.

Celldex Therapeutics stock (ISIN US15117B2025) was last at USD 31.65 on Nasdaq on October 2, 2026, down 1.65 percent from USD 32.18. The company’s barzolvolimab program delivered the central clinical update on September 22, when Celldex reported positive results from two Phase 3 studies.

Phase 3 clears key endpoints

EMBARQ-CSU1 and EMBARQ-CSU2 both met their primary UAS7 endpoint at Week 12 and all key secondary endpoints across both dose groups, according to the company release dated September 22, 2026. The trials tested barzolvolimab in adults with chronic spontaneous urticaria whose symptoms were inadequately controlled by H1 antihistamines.

The program randomized 1,939 patients, split between 963 participants in EMBARQ-CSU1 and 976 in EMBARQ-CSU2. Treatment continues through Week 52, while the placebo-controlled period ran for 24 weeks, making durability and regulatory execution the next measurable milestones.

Complete response reaches 54.0 percent

The response comparison gives the data their clearest investor relevance. In EMBARQ-CSU2, complete response at Week 24 reached 54.0 percent for the 150 mg every-four-weeks group versus 17.6 percent for placebo, while the 300 mg every-eight-weeks group reached 48.4 percent, per GlobeNewswire.

The same release reported a 49.0 percent complete response rate at Week 24 for the 150 mg group in EMBARQ-CSU1, compared with 15.4 percent for placebo. Celldex plans a Biologics License Application submission in 2027, but the trials remain ongoing and the company still needs regulatory validation before commercial assumptions can be tested.

Analysts keep targets above USD 60

On October 2, HC Wainwright reaffirmed a Buy rating and maintained a USD 64.00 price target, according to MarketBeat. That target lies 102.21 percent above the October 2 price.

MarketBeat also reported a Moderate Buy consensus with 14 analysts and an average target of USD 61.92. The stock’s clinical upside remains paired with execution risk: the company’s lead asset must preserve its Week 24 response profile through the ongoing 52-week studies and then clear the filing process.

CLDX stays below its yearly high

CLDX traded between USD 30.98 and USD 32.54 on October 2, 2026, with 2,405,740 shares changing hands. Its 52-week range was USD 22.10 to USD 45.14, and its market capitalization was USD 2.1 billion as of that date.